MedTrace Logo

Evaluate the Effect of Synbiotics on MAFLD

NCT06537882 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2025-04-03

No results posted yet for this study

Summary

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Available data indicates that probiotics may regulate the gut microbiota, while Vitamin E and omega 3 are safe and effective at treating NAFLD patients. In this study, investigators aim to investigate if the enhanced synbiotic preparation of SLP07 is efficacious in liver function improvement in subjects with MAFLD.

Conditions

  • Metabolic Dysfunction-Associated Fatty Liver Disease

Interventions

DIETARY_SUPPLEMENT

G-NiiB synbiotics formula (SLP07)

SLP07 consists of a blend of food-grade Bifidobacterium and Lactobacillus as active probiotics, omega 3, and vitamin E.

DIETARY_SUPPLEMENT

Active placebo

Active placebo contains 2mg of vitamin C with corn starch filler

Sponsors & Collaborators

  • Microbiota I-Centre (MagIC)

    collaborator UNKNOWN

  • GenieBiome Limited

    lead INDUSTRY

Principal Investigators

  • Jessica Ching, PhD · GenieBiome Limited

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-17
Primary Completion
2025-02-07
Completion
2026-06-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06537882 on ClinicalTrials.gov